Get the Stockscreener App
4.23
3.68%
0.15
Biomea Fusion Inc stock is traded at $4.23, with a volume of 839.61K.
It is up +3.68% in the last 24 hours and down -32.64% over the past month.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
See More
Previous Close:
$4.08
Open:
$4.02
24h Volume:
839.61K
Relative Volume:
0.90
Market Cap:
$153.29M
Revenue:
-
Net Income/Loss:
$-144.01M
P/E Ratio:
-1.2741
EPS:
-3.32
Net Cash Flow:
$-113.02M
1W Performance:
-25.00%
1M Performance:
-32.64%
6M Performance:
-18.50%
1Y Performance:
-69.24%
1-Day Range:
$3.96
$4.28
1-Week Range:
$3.81
$6.06
52-Week Range:
$3.61
$20.21
Biomea Fusion Inc Stock (BMEA) Company Profile
Name
Biomea Fusion Inc
Sector
Industry
Phone
(650) 980-9099
Address
900 MIDDLEFIELD ROAD, REDWOOD CITY
Compare BMEA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
4.23 | 153.29M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-24 | Initiated | Edward Jones | Buy |
| Sep-27-24 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Sep-27-24 | Upgrade | Truist | Hold → Buy |
| Aug-29-24 | Initiated | CapitalOne | Overweight |
| Jun-11-24 | Downgrade | Truist | Buy → Hold |
| Jun-07-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-24 | Initiated | Truist | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jun-26-23 | Downgrade | Jefferies | Buy → Hold |
| May-12-23 | Initiated | Barclays | Overweight |
| Mar-29-23 | Reiterated | Oppenheimer | Outperform |
| Mar-28-23 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-23 | Initiated | Citigroup | Buy |
| Jun-02-22 | Resumed | H.C. Wainwright | Buy |
| Jan-12-22 | Initiated | H.C. Wainwright | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Jefferies | Buy |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Biomea Fusion Inc Stock (BMEA) Latest News
Biomea Fusion Advances Diabetes Treatment with Positive Study Results - TipRanks
Biomea Fusion's SWOT analysis: clinical hold casts shadow on diabetes drug stock - Investing.com
Biomea Fusion shares hold with Buy rating after trial success By Investing.com - Investing.com Australia
Biomea Fusion shares hold with Buy rating after trial success - Investing.com
Biomea Fusion's (BMEA) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes - The Manila Times
Biomea Fusion Announces Positive Topline Results from - GlobeNewswire
Biomea Fusion's Diabetes Drug Shows Breakthrough Results in Phase II Trial, Achieves Key HbA1c Reductions - StockTitan
The Manufacturers Life Insurance Company Takes Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Analysts Set Biomea Fusion, Inc. (NASDAQ:BMEA) Target Price at $39.36 - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of “Buy” by Analysts - Defense World
Biomea Fusion (NASDAQ:BMEA) Receives Buy Rating from HC Wainwright - Defense World
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) - The Manila Times
Biomea Fusion to Host Conference Call to Announce Topline - GlobeNewswire
Biomea Fusion to Unveil Key Phase II Diabetes Trial Results: COVALENT-111 Data Release Set for December - StockTitan
Biomea Fusion (NASDAQ:BMEA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Biomea Fusion's SWOT analysis: stock faces challenges amid clinical hold By Investing.com - Investing.com South Africa
Biomea Fusion, Inc. (NASDAQ:BMEA) Short Interest Update - MarketBeat
Biomea Fusion's SWOT analysis: stock faces challenges amid clinical hold - Investing.com
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - The Manila Times
Biomea Fusion Announces Oral and Poster Presentations of - GlobeNewswire
Biomea Fusion Unveils Breakthrough Preclinical Data: Menin Inhibitor Boosts GLP-1 Therapy Effectiveness - StockTitan
Biomea Fusion (NASDAQ:BMEA) Earns “Buy” Rating from D. Boral Capital - Defense World
HC Wainwright Reaffirms “Buy” Rating for Biomea Fusion (NASDAQ:BMEA) - Defense World
HC Wainwright Reaffirms "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia - The Manila Times
Biomea Fusion Announces Preliminary Data from Ongoing - GlobeNewswire
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 - EIN News
Fmr LLC Increases Stock Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia - GlobeNewswire
Biomea Fusion to Reveal Groundbreaking FLT3 Inhibitor Data for Acute Leukemia Treatment - StockTitan
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biomea Fusion Grants 30,000 Stock Options to New Employee Under Inducement Plan | BMEA Stock News - StockTitan
(BMEA) Investment Report - Stock Traders Daily
Biomea Fusion's SWOT analysis: clinical hold impacts diabetes drug stock - Investing.com India
Biomea Fusion's SWOT analysis: clinical hold impacts diabetes drug stock By Investing.com - Investing.com Canada
HC Wainwright Reaffirms Buy Rating for Biomea Fusion (NASDAQ:BMEA) - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) - The Manila Times
Late-Breaker Oral Presentation Showing New Analysis from - GlobeNewswire
Biomea Fusion's Diabetes Drug Shows 1.23% HbA1c Drop in Key Patient Group | BMEA Stock News - StockTitan
We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate - Yahoo Finance
Airbnb CEO’s Counterintuitive Leadership Playbook for the $85 Billion Brand - Yahoo Finance
How To Trade (BMEA) - Stock Traders Daily
Biomea Fusion, Inc. Reveals Preclinical Data on Icovamenib and BMF-650 in Recent SEC Filing - Defense World
Biomea Fusion's SWOT analysis: clinical hold clouds diabetes drug stock outlook - Investing.com India
Biomea Fusion FY2024 EPS Estimate Raised by HC Wainwright - Defense World
HC Wainwright Forecasts Increased Earnings for Biomea Fusion - MarketBeat
Biomea Fusion (NASDAQ:BMEA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Biomea Fusion Inc Stock (BMEA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):